{"id":24032,"date":"2023-07-20T10:30:27","date_gmt":"2023-07-20T08:30:27","guid":{"rendered":"https:\/\/idibell.cat\/?p=24032"},"modified":"2023-07-20T12:43:42","modified_gmt":"2023-07-20T10:43:42","slug":"lantioxidant-natural-l-ergotioneina-preveu-la-formacio-de-pedres-de-cistina-en-un-model-de-ratoli-amb-cistinuria","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/07\/lantioxidant-natural-l-ergotioneina-preveu-la-formacio-de-pedres-de-cistina-en-un-model-de-ratoli-amb-cistinuria\/","title":{"rendered":"L&#8217;antioxidant natural L-Ergotioneina prev\u00e9 la formaci\u00f3 de pedres de cistina en un model de ratol\u00ed amb cistin\u00faria"},"content":{"rendered":"<p>La cistin\u00faria \u00e9s una malaltia gen\u00e8tica heredit\u00e0ria que afecta 1 de cada 7.000 persones. Es caracteritza per l&#8217;aparici\u00f3 recurrent de pedres de cistina al rony\u00f3 i les vies urin\u00e0ries durant tota la vida del pacient, cosa que provoca un deteriorament de la seva funci\u00f3 renal i conseq\u00fcentment de la seva qualitat de vida. A dia d&#8217;avui, no hi ha un tractament efectiu, ja que els f\u00e0rmacs disponibles no funcionen en tots els pacients o generen massa efectes secundaris.<\/p>\n<p>Ara, un projecte liderat pel grup de <a href=\"https:\/\/idibell.cat\/recerca\/area-de-medicina-translacional\/programa-de-gens-malaltia-i-terapia\/genetica-molecular-humana\/\">Gen\u00e8tica Molecular Humana<\/a> de l&#8217;IDIBELL ha demostrat que l&#8217;administraci\u00f3 de l&#8217;antioxidant L-Ergotioneina de manera preventiva i cr\u00f2nica en el model de ratol\u00ed amb aquesta malaltia va reduir el nombre de ratolins amb s\u00edmptomes o va endarrerir-ne l&#8217;aparici\u00f3.<\/p>\n<p>Aquest treball, publicat a la revista <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2213231723002021\"><em>Redox Biology<\/em><\/a>, ha estat dirigit per la Dra. Virginia Nunes, investigadora de l&#8217;IDIBELL i catedr\u00e0tica del Departament de Ci\u00e8ncies Fisiol\u00f2giques de la Facultat de Medicina i Ci\u00e8ncies de la Salut de la Universitat de Barcelona. Hi han col\u00b7laborat investigadors dels grups liderats per Rafa Artuch, Gloria Garrabou i Federico Pallard\u00f3 del Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (<a href=\"https:\/\/www.ciberer.es\/\">CIBERER<\/a>), Pablo Garcia-Roves tamb\u00e9 d&#8217;IDIBELL i la Universitat de Barcelona, i Amadeu Llebaria de l&#8217;Institut de Qu\u00edmica Avanzada de Catalunya (<a href=\"https:\/\/www.iqac.csic.es\/es\/\">IQAC-CSIC<\/a>).<\/p>\n<p>\u201cL\u2019L-Ergotioneina \u00e9s un antioxidant natural que obtenim de la dieta i que la FDA ha catalogat com a segur a dosis molt superiors de les usades en aquests ratolins\u201d, explica la Dra. Nunes. \u201cAquest compost incrementa la solubilitat de cistina a l&#8217;orina, evitant aix\u00ed la seva precipitaci\u00f3 i la formaci\u00f3 de c\u00e0lculs. A m\u00e9s, despr\u00e9s del tractament, observem la recuperaci\u00f3 de nivells antioxidants i de la funci\u00f3 mitocondrial renal\u201d, afegeix la Dra. Clara Mayayo-Vallverd\u00fa, investigadora d&#8217;IDIBELL i la UB, i primera autora de l&#8217;article.<\/p>\n<p>De fet, resultats preliminars d&#8217;aquest treball van permetre el 2021 que l\u2019L-Ergotioneina fos designada com a medicament orfe per al tractament de la cistin\u00faria per l&#8217;Ag\u00e8ncia Europea del Medicament (<a href=\"https:\/\/www.ema.europa.eu\/en\">EMA<\/a>). Amb la publicaci\u00f3 dels resultats definitius, l&#8217;equip de la Dra. Nunes aporta m\u00e9s evid\u00e8ncia sobre el potencial d&#8217;aquest antioxidant per prevenir la formaci\u00f3 de c\u00e0lculs de cistina per poder iniciar un assaig cl\u00ednic per validar-los.<\/p>\n<p>L&#8217;estudi ha estat finan\u00e7at per l&#8217;Institut de Salut Carlos III i la Fundaci\u00f3 Marat\u00f3 de TV3.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><br \/>\n<em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>El tractament amb L-Ergotioneina aconsegueix incrementar la solubilitat de la cistina a l&#8217;orina, evitant aix\u00ed la formaci\u00f3 de c\u00e0lculs o endarrerint-ne l&#8217;aparici\u00f3. Despr\u00e9s del tractament tamb\u00e9 s&#8217;observa una millora de l&#8217;estat oxidatiu i de la funci\u00f3 mitocondrial al rony\u00f3. Quan es validin els resultats en un assaig cl\u00ednic, es disposar\u00e0 d&#8217;un nou tractament preventiu per a aquesta malaltia.<\/p>\n","protected":false},"author":8,"featured_media":24033,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1],"tags":[],"class_list":["post-24032","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 18:59:31","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24032","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=24032"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24032\/revisions"}],"predecessor-version":[{"id":24035,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/24032\/revisions\/24035"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/24033"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=24032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=24032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=24032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}